Bronchoalveolar Cell Lung Cancer Completed Phase 2 Trials for Erlotinib (DB00530)

IndicationStatusPhase
DBCOND0028477 (Bronchoalveolar Cell Lung Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01557959Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerTreatment